La Trobe University is hosting a panel event on 'Innovation in medical AI', at 2024 AusBiotech on Thursday 31 October. Chaired by Michelle Gallaher, CEO, Cerulea Clinical Trials, this panel focuses on the bright future of AI brimming with potential to revolutionise healthcare in areas ranging from medical discovery to development and manufacturing.
AI is paving the way for a new age of precision medicine, personalised treatments, and enhanced efficiency in healthcare delivery. Its influence extends across cancer treatment, RNA research, infectious diseases, cardiovascular health, and personalised immunotherapies.
The session brings together four thought leaders to contribute insights from across the sector. The panel will explore important topics impacting the intersection of biotechnology and AI sectors, including:
- AI in therapeutic discovery and development
- Application of AI in clinical trials
- Cross-disciplinary skills at the intersection of biology and AI.
Speakers
- Professor Wei Xiang, Director (Australian Centre for AI in Medical Innovation – ACAMI) and Chair (La Trobe-Cisco Centre for AI and IoT), La Trobe University
- Professor Marco Herold, CEO, Olivia Newton-John Cancer Research Institute
- Dr Jia Yee Lee, Director (Strategy & Alliance), BioNTech
- Dr Michelle Perugini, CEO, Presagen.
La Trobe is also set to welcome AusBiotech delegates to its Melbourne Campus – showcasing capabilities and facilities during a pre-conference tour. Key sites include the Bio Innovation Hub, the La Trobe Institute for Molecular Sciences and the Digital Innovation Hub.
Located 14km from the Melbourne CBD, the La Trobe Melbourne Campus is home to world-class facilities, institutes and amenities built for students, researchers, industry partners and the broader community.
Additional tour stops: La Trobe Sports Park and Home of the Matilda’s, Urban Solar Farm, La Trobe Private Hospital, AgriBio, BioNTech mRNA Manufacturing Facility site, Nangak Tamboree Wildlife Sanctuary, and more.
The University's extensive research institutes and industry partnerships, including over 19 companies co-located at the Melbourne campus, enable cross-disciplinary projects that drive innovation and real-world impact in the biotech sector.
Work at the intersection of technology and biology includes applying AI, machine learning, and mathematical biology to fields such as disease modelling and digital pathology, with the goal of improving and personalising drug discovery and development.
For more information and to register for the conference, visit 2024 Ausbiotech
